Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl-Erik Andersson

Showing results (1-10 of 342) with videos related to

Pageof 35
Sort By:
BJU International|October 25, 2017
Oxidative stress and its possible relation to lower urinary tract functional pathologyKarl-Erik Andersson
Urology|March 12, 2004
New pharmacologic targets for the treatment of the overactive bladder: an updateKarl-Erik Andersson
Basic & Clinical Pharmacology & Toxicology|March 19, 2016
Potential Future Pharmacological Treatment of Bladder DysfunctionKarl-Erik Andersson
Nature Reviews. Urology|July 12, 2017
Pharmacology: Cardiovascular effects of mirabegronKarl-Erik Andersson
The Journal of Urology|July 19, 2008
How many drugs for LUTS due to BPH are too many?Karl-Erik Andersson
Current Opinion in Urology|October 22, 2014
Intraprostatic injections for lower urinary tract symptoms treatmentKarl-Erik Andersson
Therapeutics and Clinical Risk Management|May 3, 2013
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinAKarl-Erik Andersson
The Journal of Urology|March 5, 2013
Animal in vivo models of lower urinary tract dysfunction: translational valueKarl-Erik Andersson
European Urology|October 13, 2014
Words of wisdom. Re: Tissue engineering of the bladder: reality or myth? A systematic reviewKarl-Erik Andersson
Expert Opinion on Investigational Drugs|August 11, 2019
Agents in early development for treatment of bladder dysfunction - promise of drugs acting at TRP channels?Karl-Erik Andersson
Pageof 35

Showing results (1-10 of 342) with videos related to

Sort By:
Pageof 35
BJU International|October 25, 2017
Oxidative stress and its possible relation to lower urinary tract functional pathologyKarl-Erik Andersson
Urology|March 12, 2004
New pharmacologic targets for the treatment of the overactive bladder: an updateKarl-Erik Andersson
Basic & Clinical Pharmacology & Toxicology|March 19, 2016
Potential Future Pharmacological Treatment of Bladder DysfunctionKarl-Erik Andersson
Nature Reviews. Urology|July 12, 2017
Pharmacology: Cardiovascular effects of mirabegronKarl-Erik Andersson
The Journal of Urology|July 19, 2008
How many drugs for LUTS due to BPH are too many?Karl-Erik Andersson
Current Opinion in Urology|October 22, 2014
Intraprostatic injections for lower urinary tract symptoms treatmentKarl-Erik Andersson
Therapeutics and Clinical Risk Management|May 3, 2013
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinAKarl-Erik Andersson
The Journal of Urology|March 5, 2013
Animal in vivo models of lower urinary tract dysfunction: translational valueKarl-Erik Andersson
European Urology|October 13, 2014
Words of wisdom. Re: Tissue engineering of the bladder: reality or myth? A systematic reviewKarl-Erik Andersson
Expert Opinion on Investigational Drugs|August 11, 2019
Agents in early development for treatment of bladder dysfunction - promise of drugs acting at TRP channels?Karl-Erik Andersson
Pageof 35